App-Quantinova.ai

Clinical Features and Prognosis of Double Primary Malignant Neoplasms in Patients with Non-Hodgkin Lymphoma

Zhumei Zhan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Diffuse large B-cell lymphoma

N/A

The Short-Term Efficacy and Safety of Obinutuzumab Plus Chemotherapy in B-NHL with High Tumor Burden: A Real-World, Retrospective Study

Xin Wan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Obinutuzumab

Clinical Characteristics and Outcomes of Follicular Lymphoma Patients with Extranodal Involvement: Analysis of a Series of 1090 Cases in China

Zhijuan Lin - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

Rituximab

Development of a New Risk Scoring System Based on Spleen Involvement and the Lymphocyte/Monocyte Ratio for Follicular Lymphoma Patients

Chunyuan Li - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

N/A

Epidemiological Features and Clinical Outcomes Predicting Risk and Prognosis of Transformed Marginal Zone Lymphoma: A SEER-Based Population Study

Minyue Zhang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mucosa-associated lymphoid tissue lymphoma

N/A

Chidamide with Azacitidine and CHOP Treatment Plus Autologous Transplantation, Followed By Maintenance with Chidamide for Patients with Newly Diagnosed Peripheral T-Cell Lymphoma (PTCL): Interim Analysis of a Prospective,Single Center, Single-Arm, Phase 2 Trial

Chunyan Xiao - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral T-cell lymphoma

Azacitidine

Health-Related Quality of Life in Hodgkin Lymphoma Patients and Associations with Lipid Metabolism

Yu Nie - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

N/A

Real-World Study Evaluating the Efficacy of Frontline Brentuximab Vedotin Plus Chemotherapy in Newly Diagnosed Patients with Hodgkin Lymphoma: A Retrospective Analysis

Qingqing Cai - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

brentuximab vedotin

Synergistic Anticancer Effect of a Combination of Chidamide and Doxorubicin Against Peripheral T-Cell Lymphoma

Wenyu Shi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral T-cell lymphoma

Cyclophosphamide

Trial in Progress: A Phase 4 Multicenter Study of Brentuximab Vedotin Treatment in Chinese Patients with CD30-Positive Cutaneous T-Cell Lymphoma

Qian Wang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Cutaneous T-cell lymphoma

brentuximab vedotin

Glofitamab Monotherapy Demonstrates High Complete Response Rates and Manageable Safety in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies

Yu-Qin Song - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Obinutuzumab

Trial in Progress: First Report of the Phase 1/2 Study of the Safety and Efficacy of CPO107, a Bispecific Agent Targeting CD20/CD47 in CD20 Expressing Non-Hodgkin Lymphoma (NHL)

Alan P. Skarbnik - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non-Hodgkin's Lymphoma

thrombospondin-1

HZ-a-018 Is a Highly Selective and Potent BTK Inhibitor with CNS-Penetrating Profile for Central Nervous System Lymphoma

Zhuang Kang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

CNS lymphoma

Methotrexate

Dual CK1ε/PI3Kδ Inhibitor HZ-H08905, Exhibits As a Potential Therapeutic Strategy for Hematologic Malignancies

Juying Wei - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hematological malignancies

N/A

Investigation of High Dose Cytarabine Plus Zenubrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma

Zhiguang Lin - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary central nervous system lymphoma

Methotrexate

A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)

Xudong Zhang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary central nervous system lymphoma

Fotemustine

Prevalence of Cancer & Cancer Subtypes and Association with Benzene, Toluene, Ethylbenzene, and Xylene - a Study from the National Health and Nutrition Survey

Arsh Chowdhary - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Expression Signature and Prognostic Value of BCL2 Translocation for Diffuse Large B-Cell Lymphoma Patients in China

Yan Qin - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

EP300

Efficiency and Safety of Zanubrutinib Combined with R-CHOP Regimen in the Treatment of Newly Diagnosed Patients with Double Expressor Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Study

Meichen Liu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Cyclophosphamide

Preliminary Outcomes of Orelabrutinib Plus RCHOP in Treatment-Naïve Patients with Double-Expression Diffuse Large B Cell Lymphoma

Yang Yang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Cyclophosphamide

Filters

24782 Abstracts